Explanation of how these data apply to community oncologists.
Emerging BsAbs and Their Impact in Multiple Myeloma
Bispecific antibody therapy is transforming cancer treatment, especially in multiple myeloma, with ongoing studies exploring early-line and maintenance use.
Read More
Dhakal Reflects on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM
In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.
Listen
Subcutaneous Isatuximab Combo Hits Primary End Points in Phase 3 Trial
The phase 3 IRAKLIA trial of subcutaneous isatuximab met its co-primary end points in multiple myeloma.
Advancing Myeloma Treatment With Blood-Based MRD Testing
In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.
Roundtable Roundup: Choosing a Bispecific Antibody for R/R Multiple Myeloma
In separate, live events, Binod Dhakal, MD, MS; and Laahn H. Foster, MD, polled oncologists on therapeutic options for a patient with multiple myeloma and progressive disease.
Talquetamab Tolerability and Dose Interruption Considered in R/R MM
During a Case-Based Roundtable® event, Omar Nadeem, MD, and participants discussed managing toxicities of talquetamab in the second article of a 2-part series.
